S Saito1, H Iwaki. 1. Art Park Urology Hospital and Clinic, Department of Pathology, Sapporo Medical University, Japan.
Abstract
OBJECTIVES: To report on a case of mucinous carcinoma of the prostate and discuss the clinical and histopathologic features of the mucin-producing carcinoma of the prostate from a review of published reports. METHODS: Our case and 87 other previously reported cases were evaluated clinically and histologically. RESULTS: We encountered a case of mucinous carcinoma of the prostate, Stage C, which was treated by radical prostatectomy. After reviewing it and the 87 other cases, we believe that these cases of mucin-producing carcinomas can be divided into three groups: 60 cases of mucinous carcinoma, 17 cases of primary signet-ring cell carcinoma, and 11 cases of mucinous carcinoma with signet-ring cells. Mucinous carcinoma is a variant of high-grade adenocarcinoma of the prostate, wherein there is a 77.8% rate of prostate-specific antigen elevation and a similar rate (77.8%) of response to endocrine therapy. Fifty percent of patients survived 3 years and 25%, 5 years. In contrast, primary signet-ring cell carcinoma conveys one of the worst prognoses among patients with prostate cancer. There are no reliable tumor markers, and there was no response to endocrine therapy. Patients with primary signet-ring cell carcinoma had a 27.3% 3-year survival rate; none survived to 5 years. The clinical features of mucinous carcinoma with signet-ring cells are very similar to primary signet-ring cell carcinoma; again, there was no response to endocrine therapy and the 3-year survival rate was 16.7%. CONCLUSIONS: Although it has been suggested that mucinous carcinoma is a variant of high-grade adenocarcinoma of the prostate, signet-ring cell carcinoma and mucinous carcinoma with signet-ring cells are other variants of carcinoma that develop in the prostate, and their prognoses are very poor.
OBJECTIVES: To report on a case of mucinous carcinoma of the prostate and discuss the clinical and histopathologic features of the mucin-producing carcinoma of the prostate from a review of published reports. METHODS: Our case and 87 other previously reported cases were evaluated clinically and histologically. RESULTS: We encountered a case of mucinous carcinoma of the prostate, Stage C, which was treated by radical prostatectomy. After reviewing it and the 87 other cases, we believe that these cases of mucin-producing carcinomas can be divided into three groups: 60 cases of mucinous carcinoma, 17 cases of primary signet-ring cell carcinoma, and 11 cases of mucinous carcinoma with signet-ring cells. Mucinous carcinoma is a variant of high-grade adenocarcinoma of the prostate, wherein there is a 77.8% rate of prostate-specific antigen elevation and a similar rate (77.8%) of response to endocrine therapy. Fifty percent of patients survived 3 years and 25%, 5 years. In contrast, primary signet-ring cell carcinoma conveys one of the worst prognoses among patients with prostate cancer. There are no reliable tumor markers, and there was no response to endocrine therapy. Patients with primary signet-ring cell carcinoma had a 27.3% 3-year survival rate; none survived to 5 years. The clinical features of mucinous carcinoma with signet-ring cells are very similar to primary signet-ring cell carcinoma; again, there was no response to endocrine therapy and the 3-year survival rate was 16.7%. CONCLUSIONS: Although it has been suggested that mucinous carcinoma is a variant of high-grade adenocarcinoma of the prostate, signet-ring cell carcinoma and mucinous carcinoma with signet-ring cells are other variants of carcinoma that develop in the prostate, and their prognoses are very poor.
Authors: Jonathan N Warner; Leah Y Nakamura; Anna Pacelli; Mitchell R Humphreys; Erik P Castle Journal: Mayo Clin Proc Date: 2010-12 Impact factor: 7.616
Authors: Lindsey Ulkus Rodrigues; Leah Rider; Cera Nieto; Lina Romero; Anis Karimpour-Fard; Massimo Loda; M Scott Lucia; Min Wu; Lihong Shi; Adela Cimic; S Joseph Sirintrapun; Rosalie Nolley; Colton Pac; Haitao Chen; Donna M Peehl; Jianfeng Xu; Wennuan Liu; James C Costello; Scott D Cramer Journal: Cancer Res Date: 2015-03-15 Impact factor: 12.701
Authors: Manuel Cobo Dols; Santiago Muñoz Gallardo; José Peláez Angulo; Rosa Algarra García; Carlos Fuente Lupiáñez; Silvia Gil Calle; Ester Villar Chamorro; Alvaro Montesa Pino; Julia Alcaide García; Inmaculada Ales Díaz; Vanesa Gutiérrez Calderón; Francisco Carabante Ocón; Manuel Benavides Orgaz Journal: Clin Transl Oncol Date: 2005-10 Impact factor: 3.405
Authors: Antonio C Westphalen; Fergus V Coakley; John Kurhanewicz; Galen Reed; Zhen J Wang; Jeffry P Simko Journal: AJR Am J Roentgenol Date: 2009-09 Impact factor: 3.959